Accelr8 Presents First Data to the Scientific Community on Rapid Bacterial Analytical Methods

    DENVER, May 1 /PRNewswire-FirstCall/ -- Scientists from Accelr8
 Technology Corporation (Amex:   AXK) presented a combined technical poster at
 the 38th annual Oak Ridge Conference, entitled "Pushing the Technology
 Envelope III: The Next Generations of Diagnostic Testing" on April 21. The
 poster title was "Identification and growth rate quantitation of individual
 bacterial clones using a novel microfluidic concentration device." The
 poster summarized methods and results of laboratory work that demonstrate
 the performance of the analyses being designed into the company's
 BACcelr8r(TM) rapid bacterial analysis system.
     The research used the company's patent-pending Quantum Microbiology(TM)
 methods for analyzing individually identified cells. The results included
 data from experimental models for each of seven key operating
 characteristics:
     1.  Specimen preparation
     2.  Bacterial concentration and surface immobilization
     3.  Bacterial viability after immobilization
     4.  Species immuno-identification
     5.  Quantitative growth rate measurement
     6.  Growth rate comparability to standard methods
     7.  Quantitative antibiotic kill rate measurement.
     The conference was sponsored by the American Association for Clinical
 Chemistry (AACC, www.aacc.org). The AACC is a large, US-based international
 scientific/medical society of clinical laboratory professionals,
 physicians, research scientists and other individuals engaged in
 science-related clinical laboratory disciplines. The Oak Ridge Conference
 is the AACC venue for new science and technology in emerging diagnostics.
     The poster presentation represents the company's first disclosure of
 Quantum Microbiology principles to the scientific and clinical laboratory
 communities. According to David Howson, Accelr8's president, "this research
 shows that our methods produce results comparable to those from standard
 methods, but in a much shorter time. The time to results are well within
 our stated goals of two hours for identification and counts, and eight
 hours for testing antibiotic resistance. Under favorable conditions,
 standard methods require at least 24 hours."
     The reported research used standard bacterial reference strains and
 studied each step in the analytical process. "Our next steps include
 integrating all of the analytical steps into a single continuous
 procedure," Howson continued. "We also will also proceed to studies using
 known concentrations of bacteria in biological fluids. These studies will
 help to demonstrate our ability to eliminate culturing and isolation, and
 analyze bacteria extracted directly from a specimen."
     In May, the company will present a poster at the General Meeting of the
 American Society for Microbiology (ASM, www.asm.org). The ASM is the
 leading American professional society for microbiologists. The poster will
 describe
     studies on a challenging type of antibiotic resistance analysis that
 has proven difficult to implement in standard automated systems.
     "These presentations are the first in our planned pipeline of
 scientific and clinical publications," added Howson. "Hospital-acquired
 pneumonia is the number one infectious cause of mortality in the ICU. Rapid
 antibiotic resistance analysis would represent a breakthrough in addressing
 this problem. We intend ultimately to validate the BACcelr8r as achieving
 this analytical goal, and these presentations offer the first evidence that
 this will be possible."
     About Accelr8
     Accelr8 Technology Corporation (www.accelr8.com) is a developer of
 innovative materials and instrumentation for advanced applications in
 medical instrumentation, basic research, drug discovery, and bio-detection.
 In addition to its microarraying products, Accelr8 is also developing a
 rapid clinical pathogen platform, the BACcelr8r(TM), based on its
 innovative surface coatings, assay processing, and detection technologies.
     Safe Harbor for Forward-Looking Statements
     Certain statements in this news release may be "forward-looking
 statements" within the meaning of Section 27A of the Securities Act of
 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
 as amended. Statements regarding future prospects and developments are
 based upon current expectations and involve certain risks and uncertainties
 that could cause actual results and developments to differ materially from
 the forward-looking statement, including those detailed in the company's
 filings with the Securities and Exchange Commission. Accelr8 does not
 undertake an obligation to publicly update or revise any forward-looking
 statements, whether as a result of new information or future events.
 
 

SOURCE Accelr8 Technology Corporation